BPC-157 (Body Protection Compound-157)

1. Overview

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids (GEPPPGKPADDAGLV), with a molecular weight of 1419.53 g/mol. It is derived from a larger protein known as Body Protection Compound, which is naturally present in human gastric juice [1][4]. The peptide was first described and characterized in the early 1990s by Predrag Sikiric and colleagues at the University of Zagreb, Croatia, who identified its potent cytoprotective properties in animal models of gastric ulceration [3].

Unlike many peptides, BPC-157 is notable for its stability in gastric juice, which distinguishes it from most other bioactive peptides that are rapidly degraded in the acidic gastric environment [1]. This stability has made it a subject of particular interest for oral administration studies. BPC-157 has been investigated in over 100 preclinical studies across a wide range of tissue injury and disease models. Human clinical data remains extremely limited, though as of early 2026, three small pilot studies have been published: a retrospective study of intra-articular injection for knee pain (2021) [21], an intravesical injection study for interstitial cystitis (2024) [22], and an intravenous safety study (2025) [13]. Two systematic reviews published in 2025 confirmed the large gap between preclinical promise and clinical evidence [23][24].

The peptide is sometimes referred to by its pharmaceutical development codes PL-10 and PL 14736. Despite extensive animal research spanning more than three decades, BPC-157 has not received regulatory approval for therapeutic use in any jurisdiction and is classified as a prohibited substance by the World Anti-Doping Agency (WADA) [5].

Molecular Weight

1419.53 g/mol

Sequence

Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV)

Half-life

Estimated <30 minutes (IM/IV); stable in gastric juice

Routes Studied

Intraperitoneal, subcutaneous, intragastric, oral (in drinking water), topical

FDA Status

Not approved for any therapeutic use; compounding access restored via Category 1 reclassification (Feb 2026)

WADA Status

Prohibited at all times under S0 (Non-Approved Substances) since 2022

2. Mechanism of Action

The mechanisms by which BPC-157 exerts its effects are not fully elucidated, though several pathways have been identified in preclinical research. A central feature of its activity appears to involve modulation of the nitric oxide (NO) system. Studies suggest that BPC-157 interacts with the NO synthase (NOS) pathway, influencing both endothelial NOS (eNOS) and inducible NOS (iNOS) activity in a context-dependent manner, which may help explain its protective effects across multiple organ systems [2][11].

BPC-157 has been shown to promote angiogenesis, the formation of new blood vessels, at least in part through upregulation of vascular endothelial growth factor (VEGF) and its receptor VEGFR2 [2][11]. This enhanced vascular recruitment is thought to be a key driver of the accelerated wound healing and tissue repair observed in animal models. Additionally, in vitro studies using tendon fibroblasts have demonstrated that BPC-157 activates the FAK-paxillin (focal adhesion kinase-paxillin) signaling pathway, which is involved in cell migration, adhesion, and survival -- processes critical to tissue repair [6].

A 2025 narrative review by McGuire et al. provided further mechanistic clarity, identifying the Akt-eNOS axis as a key signaling node through which BPC-157 promotes angiogenesis, and confirming ERK1/2 signaling as an additional pathway facilitating endothelial and muscle repair [24].

Beyond direct tissue effects, BPC-157 appears to modulate growth factor signaling more broadly. It has been shown to enhance the expression of growth hormone receptors in tendon fibroblasts in a dose- and time-dependent manner [7], and it interacts with several standard angiogenic growth factors including EGF, FGF, and HGF in the context of gastrointestinal and musculoskeletal healing [11]. The peptide also interacts with the dopaminergic system; early studies demonstrated that BPC-157 modulates dopamine and serotonin turnover, which may contribute to its observed effects on gut motility, mucosal protection under stress, and potential neuroprotective properties [10][14].

3. Pharmacokinetics

Absorption

BPC-157 is distinguished from most bioactive peptides by its exceptional stability in the acidic environment of the stomach. Sikiric and colleagues demonstrated that BPC-157 remains intact in human gastric juice for extended periods (over 24 hours), a property that is virtually unique among known peptides and that underpins its potential for oral administration [1][4]. This stability is attributed to the peptide's particular amino acid composition, which lacks aromatic residues and features a high proportion of proline residues that confer resistance to pepsin and other gastric peptidases.

Oral (intragastric) administration has been shown to produce systemic biological effects comparable to parenteral routes in multiple animal models. In the ligament healing study by Cerovecki et al. (2010), oral BPC-157 delivered in drinking water achieved equivalent healing outcomes to intraperitoneal injection at 10 mcg/kg, suggesting meaningful oral bioavailability despite the absence of formal bioavailability quantification [8]. Intraperitoneal (IP) and subcutaneous (SC) routes have been the most commonly used parenteral routes in preclinical research, with both showing consistent efficacy. The 2025 pilot study established that intravenous administration at doses up to 20 mg is feasible in humans [13].

Absolute bioavailability values for any route have not been formally published using conventional pharmacokinetic assay methods, largely because validated plasma assays for BPC-157 at physiologically relevant concentrations have not been widely available. The peptide's low molecular weight (1419.53 Da) is theoretically compatible with paracellular absorption across the gastrointestinal mucosa.

Distribution

Formal volume of distribution (Vd) studies have not been published for BPC-157. However, the peptide's effects across diverse organ systems -- including the gastrointestinal tract, musculoskeletal tissues, brain, liver, and vasculature -- suggest broad tissue distribution following systemic absorption [1][2][14].

Evidence for blood-brain barrier (BBB) penetration comes primarily from functional studies rather than direct pharmacokinetic measurements. BPC-157 has demonstrated central nervous system effects in multiple animal models, including modulation of dopamine and serotonin turnover, antidepressant-like activity, and neuroprotective effects against centrally-acting neurotoxins [10][12][14]. Sikiric et al. (2023) presented evidence that BPC-157 influences brain-gut axis signaling, which implies that the peptide or an active metabolite reaches the central nervous system in sufficient concentrations to exert pharmacological effects [14]. Whether this reflects direct BBB crossing, circumventricular organ access, or indirect signaling through vagal or humoral pathways remains to be definitively established.

In musculoskeletal tissue studies, BPC-157 has been detected functionally in tendons, ligaments, muscles, and bone, with enhanced local vascular recruitment suggesting that tissue penetration is facilitated by its pro-angiogenic activity [2][8][11].

Metabolism and Stability

BPC-157's resistance to enzymatic degradation is a defining pharmacological feature. The peptide is stable in human gastric juice for periods exceeding 24 hours, in stark contrast to most endogenous and synthetic peptides, which are degraded within minutes [1][4]. This resistance extends to partial stability against common serum peptidases, though the peptide is eventually subject to degradation by aminopeptidases and carboxypeptidases in plasma.

The specific metabolic pathways and metabolites of BPC-157 have not been fully characterized. Given its peptide structure, it is presumed to be ultimately degraded into constituent amino acids through standard peptidase activity in tissues and plasma. No hepatic cytochrome P450 interactions have been identified or studied, which is consistent with the metabolism of other small peptides.

Half-Life

The plasma half-life of BPC-157 has not been precisely determined using standard pharmacokinetic sampling methods. Based on its peptide nature and indirect evidence from dosing studies, the systemic half-life following injection (IM/IV/SC) is estimated to be relatively short, likely on the order of minutes to 30 minutes, which is typical for peptides of this size [4]. However, this short plasma half-life appears to be offset by the peptide's ability to initiate sustained biological cascades -- including gene expression changes (such as Egr-1 upregulation and VEGF induction) and cellular signaling events (FAK-paxillin activation) -- that persist well beyond the peptide's presence in circulation [2][6][15].

The effective biological half-life, in terms of duration of therapeutic effect, appears considerably longer than the plasma half-life, as evidenced by the efficacy of once-daily dosing regimens in animal studies [8][9].

4. Researched Applications

Wound and Tissue Healing

Evidence level: Moderate (animal studies)

BPC-157 has been studied across a broad range of wound and tissue healing models in animals. In skin wound models, it has been reported to enhance granulation tissue formation and collagen organization, with potential involvement of early growth response gene-1 (Egr-1) expression [15]. In gastric and intestinal ulcer models, BPC-157 demonstrated cytoprotective effects and accelerated mucosal healing, including in lesions induced by NSAIDs, ethanol, and stress [1][3]. The peptide also promoted healing in colocutaneous fistula models and short bowel syndrome models in rats [1].

Gastrointestinal Protection

Evidence level: Moderate (animal studies; limited human IBD trial data)

Gastrointestinal protection was among the earliest studied applications of BPC-157 [3]. The peptide has shown consistent gastroprotective effects in animal models of ulceration induced by restraint stress, ethanol, indomethacin, and capsaicin-mediated neurotoxicity [3]. It has also been studied in NSAID-induced gastrointestinal toxicity models, where it appeared to counteract mucosal damage [1]. BPC-157 entered early-phase clinical trials for inflammatory bowel disease (IBD) under the designation PL 14736, though comprehensive results from these trials have not been published in the peer-reviewed literature [1][4]. More recently, research has explored BPC-157's potential role in the brain-gut axis, suggesting it may influence bidirectional gut-brain signaling pathways [14].

Neuroprotective Effects

Evidence level: Preliminary (animal studies)

Animal studies have suggested that BPC-157 may have neuroprotective properties. Research has examined its effects in models of traumatic brain injury, peripheral nerve injury, and dopaminergic system dysfunction [12]. The peptide has been reported to interact with both dopaminergic and serotonergic neurotransmitter systems, and some studies have observed antidepressant-like effects in animal behavioral models [10][12]. BPC-157 has also been investigated for potential protective effects against neurotoxin-induced damage in rodent models [12]. These findings remain at an early stage and have not been evaluated in human clinical trials.

Musculoskeletal Healing

Evidence level: Moderate (animal studies and in vitro)

A significant body of preclinical research has examined BPC-157 in musculoskeletal injury models. In rats with transected Achilles tendons, BPC-157 accelerated healing and stimulated tendocyte proliferation in vitro [6]. The peptide improved biomechanical, functional, and histological outcomes in transected quadriceps muscle in rats [9]. Ligament healing studies demonstrated that BPC-157 improved medial collateral ligament repair over 90 days through multiple routes of administration [8]. A 2019 systematic review by Gwyer et al. found consistently positive effects across soft tissue injury models but noted the absence of human clinical trial data as a significant limitation [5].

Two major reviews published in 2025 further evaluated this evidence base. Vasireddi et al. conducted a systematic review of BPC-157 in orthopaedic sports medicine, analyzing 36 studies (35 preclinical, 1 clinical) from 1993 to 2024. They confirmed that BPC-157 improved functional, structural, and biomechanical outcomes across muscle, tendon, ligament, and bony injury models, while highlighting that only a single clinical study existed [23]. McGuire et al. published a narrative review describing BPC-157 as demonstrating "robust regenerative and cytoprotective effects" in preclinical models but concluded that the peptide should be considered investigational until well-designed clinical trials are conducted [24].

In the only published clinical study of musculoskeletal application, Lee and Burgess (2021) retrospectively reviewed 16 patients who received intra-articular BPC-157 injections for chronic knee pain, reporting that 14 of 16 patients experienced significant pain relief persisting for 6 months to 1 year [21]. While promising, this was an uncontrolled retrospective study with inherent limitations.

Interstitial Cystitis

Evidence level: Preliminary (single pilot study)

A 2024 pilot study by Lee and Burgess examined BPC-157 for treatment-refractory interstitial cystitis (bladder pain syndrome) in 12 women aged 39-76 who had failed pentosan polysulfate therapy [22]. Patients received intravesical injection of 10 mg BPC-157 around areas of bladder inflammation during a single cystoscopy procedure. Complete symptom resolution was reported by 10 of 12 patients (100% success rating), with the remaining 2 patients reporting approximately 80% improvement. No adverse events were reported. While these results are notable, the study was uncontrolled, conducted at a single private clinic, and the improvements could reflect placebo effect or effects of the invasive procedure itself. This represents the first reported use of intravesical BPC-157 for any indication.

5. Clinical Evidence Summary

6. Dosing in Research

The following table summarizes doses used in published research studies. These are not therapeutic recommendations. BPC-157 is not approved for human use, and optimal dosing in humans has not been established.

7. Dose-Response Relationships

Effective Dose Ranges Across Models

BPC-157 has demonstrated efficacy across a remarkably wide dose range in preclinical studies, spanning from nanogram to microgram per kilogram quantities. This broad therapeutic window is one of the peptide's distinguishing characteristics.

Microgram dosing (10 mcg/kg): This has been the most commonly studied parenteral dose across the majority of animal models, including gastric ulcer protection [3], tendon healing [6], muscle repair [9], and ligament regeneration [8]. At this dose, consistent and statistically significant effects have been observed across virtually all studied indications.

Nanogram dosing (10 ng/kg): Remarkably, BPC-157 has demonstrated efficacy even at nanogram-per-kilogram doses. Staresinic et al. (2006) showed that 10 ng/kg -- a dose 1,000-fold lower than the standard microgram dose -- still produced significant improvement in transected quadriceps muscle healing, although the magnitude of effect was somewhat reduced compared to the 10 mcg/kg dose [9]. This suggests an extremely low minimum effective dose threshold.

In vitro concentrations: Cell culture studies have used concentrations ranging from 1 ng/mL to 100 ng/mL, with dose-dependent effects observed on tendon fibroblast proliferation, migration, and growth hormone receptor expression [6][7].

Human dosing (2021-2025): The three published human studies have used varying routes and doses. The knee pain study (2021) used intra-articular injection at unspecified doses [21]. The interstitial cystitis study (2024) used intravesical injection of 10 mg total [22]. The IV safety study (2025) used doses up to 20 mg (approximately 250-330 mcg/kg for a typical adult), which is substantially higher than the standard animal dose on a per-kilogram basis [13].

Dose-Response Curve Characteristics

Available evidence does not clearly indicate a bell-shaped (inverted-U) dose-response curve for BPC-157, which is notable because bell-shaped responses are common among peptide therapeutics. Instead, the data suggest a monotonic dose-response relationship within the ranges tested, with higher doses generally producing greater or at least equivalent effects compared to lower doses [9]. However, it should be noted that relatively few studies have included multiple dose groups, so the full shape of the dose-response curve remains incompletely characterized. No ceiling effect or paradoxical dose-response reversal has been reported in published literature.

Oral vs. Injectable Efficacy Comparison

A particularly important finding is that oral and injectable routes appear to produce comparable therapeutic outcomes at appropriate doses. In the Cerovecki et al. (2010) ligament healing study, BPC-157 administered orally in drinking water (0.16 mcg/mL, approximately 2 mcg/day per rat) achieved biomechanical and histological outcomes similar to those observed with intraperitoneal injection at 10 mcg/kg [8]. This oral efficacy at apparently lower total doses than the injectable route may reflect continuous exposure through ad libitum drinking, the peptide's unique gastric stability, or potentially enhanced local effects during gastrointestinal absorption [1].

For gastrointestinal indications specifically, oral administration may offer advantages through direct local effects on the gastric and intestinal mucosa in addition to any systemic activity [1][3][16]. For musculoskeletal and other non-GI indications, the relative efficacy of oral vs. injectable routes has been less thoroughly compared, though positive results have been reported for both [8].

8. Safety and Side Effects

Preclinical Toxicology

In the extensive preclinical literature spanning over three decades, BPC-157 has been reported to have a remarkably favorable safety profile. Formal acute toxicity studies in rodents failed to identify a lethal dose: no LD50 has been established because researchers were unable to achieve lethal toxicity even at doses vastly exceeding the therapeutic range [4]. Sikiric et al. (1999) reported that BPC-157 was safe in rats and mice at doses up to and exceeding the therapeutic dose by several orders of magnitude, with no mortality observed at the highest tested doses. This absence of identifiable lethal toxicity is unusual among pharmacologically active compounds and has been consistently reported across multiple independent assessments [4][20].

Subchronic toxicity studies in rodents using daily administration for periods up to 90 days have not revealed significant organ toxicity, hematological abnormalities, or histopathological changes in major organs at therapeutic dose levels [4][8]. No hepatotoxicity, nephrotoxicity, or cardiotoxicity has been reported in any published preclinical study. The peptide has not shown mutagenic potential in available genotoxicity assessments [4].

Human Safety Data (2021-2025)

As of early 2026, three small human studies have been published, collectively involving approximately 30 subjects. In the knee pain study (2021, n=16) and the interstitial cystitis study (2024, n=12), no adverse events were reported in any participant [21][22]. However, neither study was designed primarily as a safety assessment, and neither included a control group.

The most rigorous safety assessment came from a 2025 pilot study by Vukojevic et al. [13]. Key details of this study include:

• Design: Open-label, single-center pilot study in 2 healthy adult volunteers
• Route and dose: Single intravenous infusion at escalating doses up to 20 mg
• Monitoring: Comprehensive safety monitoring including vital signs, ECG, standard hematology and biochemistry panels, and adverse event reporting
• Results: No adverse effects were observed at any dose level. All vital signs, laboratory parameters, and ECG readings remained within normal limits throughout the observation period
• Limitations: The extremely small sample size (n=2), single-dose design, lack of a control group, and short follow-up period severely limit the generalizability of these findings. This study establishes only that acute IV administration at these doses did not produce immediately apparent toxicity; it does not establish safety in any comprehensive sense

LD50 and Acute Toxicity

No LD50 value has been identified for BPC-157 in any species tested. This is documented in the foundational pharmacology review by Sikiric et al. (1999), which noted that lethal toxicity could not be achieved at the doses tested in rodent models [4]. While the absence of identifiable lethal toxicity is noteworthy, it should be interpreted with appropriate caution -- it indicates very low acute toxicity rather than absolute safety, and it does not address chronic toxicity, organ-specific effects at high cumulative exposures, or delayed adverse effects.

Reproductive and Developmental Toxicity

No formal reproductive toxicity, teratogenicity, or developmental toxicity studies have been published for BPC-157. The effects of the peptide on fertility, embryonic development, fetal growth, and postnatal development are entirely unknown. Given the peptide's pro-angiogenic activity and influence on growth factor signaling, which are processes critical to normal embryonic development, the absence of reproductive safety data represents a significant gap. BPC-157 should be considered contraindicated during pregnancy and lactation until adequate safety data becomes available.

Known Contraindications

No formal contraindications have been established through clinical study, as BPC-157 is not an approved therapeutic agent. However, based on its known pharmacological mechanisms, the following theoretical contraindications should be considered:

• Active malignancy or history of cancer: BPC-157's pro-angiogenic effects (VEGF upregulation, enhanced vascular recruitment) could theoretically promote tumor vascularization and growth [2][11][18]. No studies have examined BPC-157 in tumor-bearing animals or cancer patients.
• Conditions involving pathological angiogenesis: Diabetic retinopathy, macular degeneration, and other conditions characterized by aberrant blood vessel growth could theoretically be worsened.
• Pregnancy and lactation: Due to complete absence of reproductive safety data.

Drug Interactions

Systematic drug interaction studies have not been conducted for BPC-157. However, preclinical research provides some insights into potential interactions:

• NSAIDs: BPC-157 has been shown to counteract NSAID-induced gastrointestinal toxicity in animal models [3][16]. This suggests a pharmacodynamic interaction, though whether this interaction extends to modifying the therapeutic effects of NSAIDs (anti-inflammatory, analgesic) is unknown.
• Dopaminergic agents: BPC-157 modulates dopamine turnover and interacts with dopaminergic pathways [10][12]. Theoretical interactions with L-DOPA, dopamine agonists, or antipsychotic medications (dopamine antagonists) should be considered.
• Alcohol: Animal studies have examined BPC-157 in the context of alcohol-induced organ damage, with protective effects observed [1]. Whether this interaction has clinical implications for alcohol metabolism or toxicity in humans is unknown.
• Anticoagulants and antiplatelet agents: Given BPC-157's effects on vascular function and angiogenesis, interactions with drugs affecting hemostasis cannot be excluded.

Ongoing Safety Uncertainties

What is not known is equally important. Long-term safety data in humans is essentially absent. The vast majority of studies have been conducted in rodents over relatively short durations. Key areas of remaining uncertainty include:

• Angiogenesis and tumor risk: BPC-157 promotes angiogenesis and upregulates VEGF [2][11]. Theoretically, enhanced angiogenesis could support the growth of existing tumors or pre-cancerous lesions, though this has not been directly studied or observed in published BPC-157 research. This remains a theoretical concern that warrants investigation.
• Long-term organ effects: The effects of chronic BPC-157 administration on liver, kidney, and cardiovascular function in humans are unknown.
• Immunogenicity: Whether repeated administration of BPC-157 can elicit an immune response or antibody formation has not been studied. As a 15-amino-acid peptide, it is below the typical threshold for immunogenicity, but carrier-protein conjugation or aggregation could theoretically alter this.
• Purity and contamination risks: As BPC-157 is not manufactured under pharmaceutical-grade regulatory oversight for consumer products, purity and contamination of commercially available preparations are significant practical concerns.

9. Comparative Effectiveness

BPC-157 vs. Proton Pump Inhibitors for Gastric Ulcers

Proton pump inhibitors (PPIs) such as omeprazole are the established standard of care for gastric ulcers, with well-documented efficacy in reducing gastric acid secretion and promoting ulcer healing in humans. BPC-157 operates through fundamentally different mechanisms: rather than suppressing acid production, it promotes mucosal healing through angiogenesis, cytoprotection, and modulation of the NO system [1][2][3].

In animal models, BPC-157 has demonstrated gastroprotective effects comparable to or exceeding those of standard anti-ulcer agents in certain contexts, particularly in NSAID-induced and stress-induced ulcer models [3][16]. Importantly, BPC-157 appears to address tissue repair at a cellular level rather than merely suppressing the causative acid environment. This suggests a potentially complementary rather than competitive role relative to PPIs. However, no head-to-head comparison with PPIs has been conducted in human clinical trials, and the animal model data cannot be directly extrapolated to predict relative clinical efficacy in humans.

PPIs have an extensive human safety and efficacy record spanning decades. BPC-157 has no comparable human evidence base.

BPC-157 vs. NSAIDs for Inflammation

NSAIDs reduce inflammation primarily through cyclooxygenase (COX) inhibition, with well-established analgesic and anti-inflammatory efficacy but significant gastrointestinal and cardiovascular side effects. BPC-157's relationship with NSAIDs is notable: rather than functioning as an anti-inflammatory agent through the same pathway, BPC-157 has been shown to counteract NSAID-induced gastrointestinal damage while potentially preserving the anti-inflammatory benefit [16].

BPC-157 has not been directly compared to NSAIDs as an anti-inflammatory agent. Its mechanism of action involves tissue repair and cytoprotection rather than direct suppression of inflammatory mediator synthesis. In animal models of inflammatory conditions, BPC-157 appears to accelerate resolution of inflammation and promote tissue healing, but it has not demonstrated the acute analgesic properties characteristic of NSAIDs [1][4]. The two classes of agents likely operate through complementary rather than overlapping mechanisms.

BPC-157 vs. Standard Wound Care

Standard wound care includes debridement, moist wound healing, growth factor application (e.g., becaplermin/PDGF for diabetic foot ulcers), and advanced dressings. BPC-157 has shown wound-healing acceleration in animal models through enhanced granulation tissue formation, collagen organization, and angiogenesis [15][18].

Tkalcevic et al. (2007) demonstrated that topical application of PL 14736 (BPC-157) enhanced wound healing with superior collagen organization and Egr-1 expression compared to controls [15]. However, these results are from controlled animal studies and have not been compared against standard wound care protocols or approved growth factor therapies in clinical settings.

BPC-157 vs. TB-500 (Thymosin Beta-4)

TB-500 (a synthetic fragment of Thymosin Beta-4) and BPC-157 are frequently discussed together in the context of tissue repair peptides. Both promote healing, but through partially distinct mechanisms:

• BPC-157 primarily acts through NO system modulation, VEGF-mediated angiogenesis, FAK-paxillin signaling, and growth hormone receptor upregulation [2][6][7][11]
• TB-500 acts primarily through actin sequestration, cell migration promotion, and anti-inflammatory effects via different signaling cascades

TB-500 has a somewhat larger body of basic science research and a better-characterized molecular mechanism (G-actin sequestration). However, BPC-157 has been studied in a broader range of tissue injury models. No head-to-head comparisons between the two peptides have been published. Both remain without regulatory approval for human therapeutic use.

BPC-157 vs. GHK-Cu (Copper Peptide)

GHK-Cu is a naturally occurring tripeptide-copper complex with documented roles in wound healing, collagen synthesis, and anti-inflammatory activity. Compared to BPC-157:

• GHK-Cu has better-characterized mechanisms at the molecular level, with documented effects on over 4,000 genes. It has established applications in cosmetic dermatology with commercially available topical formulations
• BPC-157 has been studied across a broader range of internal organ systems (gastrointestinal, musculoskeletal, neurological) and has demonstrated systemic effects via multiple routes of administration, including oral

GHK-Cu's advantages include its natural occurrence in human plasma, commercially available formulations, and longer track record in topical applications. BPC-157's advantages include its unique gastric stability enabling oral dosing and its broader range of studied systemic applications. No direct comparisons have been published.

10. Regulatory Status

United States (FDA): BPC-157 is not approved by the U.S. Food and Drug Administration for any therapeutic indication. It has not completed the clinical trial process required for drug approval. In late 2023, the FDA placed BPC-157 on the Category 2 Bulk Drug Substances list, citing significant safety concerns including immunogenicity and lack of human clinical data, effectively prohibiting its preparation by compounding pharmacies under Section 503A.

In a significant regulatory reversal, on February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 peptides previously placed on the Category 2 restricted list -- including BPC-157 -- would be moved back to Category 1, restoring legal access through licensed compounding pharmacies with a physician's prescription. As of March 2026, the formal FDA rulemaking to implement this reclassification is pending; no Federal Register notice has been published. It is important to note that Category 1 reclassification is not equivalent to FDA approval -- it permits compounding under physician oversight but does not establish safety or efficacy through the standard drug approval process.

WADA (World Anti-Doping Agency): BPC-157 has been listed on the WADA Prohibited List since 2022, classified under category S0: Non-Approved Substances. It is prohibited at all times, both in and out of competition. No Therapeutic Use Exemption (TUE) pathway is available because the substance is not an approved therapeutic agent in any country. As of the 2025-2026 cycle, the NCAA has also explicitly listed BPC-157 in its banned substance handbook, removing any prior ambiguity for collegiate athletes. Testing laboratories have developed high-resolution mass spectrometry methods capable of detecting synthetic BPC-157 markers with increasing sensitivity.

European Union: BPC-157 falls under Novel Foods regulations in the EU, meaning it would require pre-market authorization for sale as a food or supplement. It is not approved as a medicinal product in any EU member state.

11. Related Peptides

See also: TB-500 (Thymosin Beta-4), GHK-Cu (Copper Peptide), LL-37 (Cathelicidin), KPV (Alpha-MSH Fragment)

12. References

1. [1] Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, et al. (2011). Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design. DOI PubMed
2. [2] Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, et al. (2018). Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157. Vascular recruitment and gastrointestinal tract healing. Current Pharmaceutical Design. DOI PubMed
3. [3] Sikiric P, Seiwerth S, Grabarevic Z, Rucman R, Petek M, Jagic V, et al. (1996). Beneficial effect of a novel pentadecapeptide BPC 157 on gastric lesions induced by restraint stress, ethanol, indomethacin, and capsaicin neurotoxicity. Digestive Diseases and Sciences. DOI PubMed
4. [4] Sikiric P, Seiwerth S, Grabarevic Z, Petek M, Rucman R, Turkovic B, et al. (1999). The pharmacological properties of the novel peptide BPC 157 (PL-10). Inflammopharmacology. DOI PubMed
5. [5] Gwyer D, Wragg NM, Wilson SL. (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research. DOI PubMed
6. [6] Chang CH, Tsai WC, Hsu YH, Pang JH. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. DOI PubMed
7. [7] Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. (2014). Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. DOI PubMed
8. [8] Cerovecki T, Bojanic I, Brcic L, Radic B, Vukoja I, Seiwerth S, Sikiric P. (2010). Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. Journal of Orthopaedic Research. DOI PubMed
9. [9] Staresinic M, Petrovic I, Novinscak T, Jukic I, Pevec D, Suknaic S, et al. (2006). Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157. Journal of Orthopaedic Research. DOI PubMed
10. [10] Sikiric P, Seiwerth S, Grabarevic Z, Rucman R, Petek M, Jagic V, et al. (1997). Pentadecapeptide BPC 157 interactions with adrenergic and dopaminergic systems in mucosal protection in stress. Digestive Diseases and Sciences. DOI PubMed
11. [11] Sikiric P, Seiwerth S, Rucman R, Kolenc D, Vuletic LB, Drmic D, et al. (2018). BPC 157 and standard angiogenic growth factors. Gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healing. Current Pharmaceutical Design. DOI PubMed
12. [12] Sikiric P, Rucman R, Brcic L, Seiwerth S, et al. (2022). Pentadecapeptide BPC 157 and the central nervous system. Neural Regeneration Research. PubMed
13. [13] Vukojevic J, Vrdoljak B, Malekinusic D, et al. (2025). Safety of intravenous infusion of BPC157 in humans: a pilot study. Therapeutic Advances in Gastroenterology. PubMed
14. [14] Sikiric P, Seiwerth S, Rucman R, et al. (2023). Stable gastric pentadecapeptide BPC 157 may recover brain-gut axis and gut-brain axis function. Pharmaceuticals. DOI PubMed
15. [15] Tkalcevic VI, Cuzic S, Brajsa K, Mildner B, Bokulic A, Situm K, et al. (2007). Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression. European Journal of Pharmacology. DOI PubMed
16. [16] Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, et al. (2013). Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157. Current Pharmaceutical Design. DOI PubMed
17. [17] Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, et al. (2012). Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. Current Medicinal Chemistry. DOI PubMed
18. [18] Seiwerth S, Brcic L, Vuletic LB, Kolenc D, Aralica G, Misic M, et al. (2014). BPC 157 and blood vessels. Current Pharmaceutical Design. DOI PubMed
19. [19] Sikiric P, Drmic D, Sever M, Klicek R, Brcic L, Seiwerth S, et al. (2020). Fistulas healing. Stable gastric pentadecapeptide BPC 157 therapy. Current Pharmaceutical Design. DOI PubMed
20. [20] Sikiric P, Rucman R, Turkovic B, Sever M, Klicek R, Radic B, et al. (2018). Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157. Robert's cytoprotection, adaptive cytoprotection, organoprotection, and Robert's prostaglandin mechanisms revisited. Current Pharmaceutical Design. DOI PubMed
21. [21] Lee M, Burgess J. (2021). Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine. PubMed
22. [22] Lee M, Burgess J. (2024). Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Alternative Therapies in Health and Medicine. PubMed
23. [23] Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. DOI PubMed
24. [24] McGuire FP, Martinez JR, et al. (2025). Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine. DOI PubMed